Valuation : Gabather AB

Market Cap 18.31M 1.91M 1.64M 1.55M 1.41M 2.63M 181M 2.64M 7.08M 92.46M 7.16M 7.01M 293M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 15.17M 1.58M 1.36M 1.28M 1.17M 2.18M 150M 2.19M 5.86M 76.59M 5.93M 5.8M 243M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
90.95%
Yield 2024 *
-
Yield 2025 -
1 week-5.66%
Current month-16.67%
1 month-13.79%
3 months-26.47%
6 months-43.40%
Current year+9.49%
1 week 0.03
Extreme 0.0274
0.03
1 month 0.03
Extreme 0.0274
0.04
Current year 0.02
Extreme 0.023
0.1
1 year 0.02
Extreme 0.023
0.1
3 years 0.02
Extreme 0.023
4.2
5 years 0.02
Extreme 0.023
6.55
10 years 0.02
Extreme 0.023
61.6
Manager TitleAgeSince
Chief Executive Officer - 01/10/2018
Chief Operating Officer - 01/01/2018
Chief Tech/Sci/R&D Officer - 01/01/2018
Director TitleAgeSince
Director/Board Member - 01/09/2014
Director/Board Member 60 03/11/2014
Chairman - 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.67%-5.66%-25.00%-98.72% 1.91M
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.51%-5.50%+31.47%+75.35% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.55%+26.01%+10.96% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.45%-4.05%+19.16%-18.67% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.71%-5.41%+506.15% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -0.74%-1.60%+33.91%+147.68% 27.64B
Weighted average by Cap. -0.69%-1.87%+36.60%+139.15%

Financials

2024 2025
Net sales - -
Net income -7.75M -807K -695K -654K -596K -1.12M -76.83M -1.12M -3M -39.14M -3.03M -2.97M -124M -4.65M -484K -417K -393K -358K -669K -46.1M -672K -1.8M -23.48M -1.82M -1.78M -74.4M
Net Debt -878K -91.43K -78.68K -74.08K -67.5K -126K -8.7M -127K -339K -4.43M -343K -336K -14.04M -3.14M -327K -282K -265K -242K -452K -31.14M -454K -1.21M -15.87M -1.23M -1.2M -50.27M
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
10/09/26 SEK 0.0280 -6.67% 921,000
09/09/26 SEK 0.0300 +3.45% 733,916
08/09/26 SEK 0.0290 -6.45% 2,831,959
07/09/26 SEK 0.0310 0.00% 873,483
04/09/26 SEK 0.0310 -2.52% 1,182,116
  1. Stock Market
  2. Stocks
  3. GABA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!